Leadingtac Announces First Healthy Volunteer Dosed in a Phase 1 Clinical Program of LT-002, a Potentially best-in-class IRAK4 degrader
2024-06-26
Shanghai Leadingtac Pharmaceutical Co., Ltd. (hereinafter referred to as "Leadingtac"), a clinical-stage biopharmaceutical company focused on the development of protein degrader for the treatment of chronic inflammatory and autoimmune diseases, announced on June 25th that the first healthy volunteer has been dosed in Phase 1 trial evaluating the safety, pharmacokinetic profile and food effects of LT-002.
Learn More